Chemical formula: CāFā Molecular mass: 188.019 g/mol PubChem compound: 6432
When used in conjunction with diagnostic ultrasound, perflutren provides opacification of cardiac chambers, improvement in delineation of endocardial borders, enhancement of the Doppler signal, and visualisation of wall motion and blood flow within the heart.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| V08DA01 | V Various → V08 Contrast media → V08D Ultrasound contrast media → V08DA Ultrasound contrast media | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| DEFINITY Suspension for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| OPTISON Dispersion for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Perflutren is an active ingredient of these brands:
Canada (CA)Cyprus (CY)
Finland (FI)
France (FR)
New Zealand (NZ)South Africa (ZA)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
Ā© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
